Johnson & Johnson (NYSE: JNJ) FY Conference Summary Company Overview - **Company**: Johnson & Johnson - **Date of Conference**: March 03, 2026 - **Key Speaker**: Joe Wolk, Executive Vice President and CFO Core Industry Insights Pharmaceutical Sector - **STELARA Loss of Exclusivity**: The company successfully navigated the loss of exclusivity for STELARA, which was anticipated and managed effectively, leading to a growth of nearly 15% in the pharmaceutical business when excluding the impact of STELARA [14][15] - **Historical Context**: Johnson & Johnson has previously overcome similar challenges, such as with REMICADE in 2018, demonstrating resilience in its pharmaceutical portfolio [14] MedTech Sector - **Acquisitions**: Strategic acquisitions of Abiomed and Shockwave have strengthened the cardiovascular franchise, leading to more predictable growth in the MedTech sector [14][19] - **Separation of Orthopaedics**: The decision to separate the orthopaedics business is aimed at focusing on higher growth and higher margin businesses, which is expected to enhance overall portfolio performance [15][35] Financial Performance and Projections - **Stock Performance**: The stock had a strong performance in 2025, attributed to both the MedTech and Innovative Medicine sectors [8][10] - **Growth Targets**: The company is targeting double-digit growth as an enterprise moving forward, with expectations of improved performance in 2026 [16][30] - **MedTech Growth Rate**: Current growth for the MedTech unit is projected at 5%-7%, with potential to exceed this range post-orthopaedic separation [30][35] Product and Innovation Highlights Vision and Surgery - **Vision Market**: The company holds a leadership position in contact lenses, with significant opportunities for growth as only 10% of those needing corrective lenses currently use contact lenses [20] - **Surgery Innovations**: The launch of new products like TECNIS and PureC is expected to drive growth in the surgery segment, particularly for cataract procedures [21] Electrophysiology - **Pulsed Field Ablation (PFA)**: The company is focusing on improving its PFA platform, which faced initial challenges but is expected to perform better in 2026 [45][46] - **CARTO System**: The CARTO mapping system is considered the gold standard, with ongoing innovations expected to enhance its capabilities and maintain market leadership [65][66] Strategic Initiatives - **M&A Strategy**: Johnson & Johnson's approach to mergers and acquisitions is opportunistic, focusing on strategic fit and scientific capabilities rather than market timing [37][38] - **Portfolio Management**: The company has been active in optimizing its portfolio, having deployed approximately $56 billion in capital on acquisitions over the past three years [41][42] Operational Considerations - **Cost Structure**: The separation of the orthopaedics business is expected to help streamline operations and reduce stranded costs, contributing to margin improvements [93][99] - **Operating Margin Guidance**: The company anticipates at least a 50 basis point improvement in pre-tax margins for 2026, driven by revenue growth and cost management [96][99] Other Notable Points - **Geopolitical Impact**: The ongoing conflict in the Middle East has not significantly impacted the company's operations, thanks to its geographical diversity and focus on employee safety [61][62] - **Future Outlook**: The company is optimistic about its growth trajectory, with a focus on ensuring successful product launches and maintaining market leadership across its franchises [80][82]

Core Insights - Palvella Therapeutics has appointed Dr. Vimal Patel as Senior Vice President of Medical Affairs, bringing over 25 years of experience in dermatology and immunology to the role [1][2][3] - Dr. Patel will lead the Medical Affairs organization to enhance scientific engagement, KOL collaboration, and disease state awareness for the QTORIN™ programs targeting serious, rare skin diseases [1][2] Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious, rare skin diseases without FDA-approved treatments [5][6] - The company is developing a pipeline based on its patented QTORIN™ platform, with lead candidates including QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin [6][7] Leadership Experience - Dr. Patel previously served at Incyte as Dermatology Therapeutic Area Head, where he led medical strategy for various dermatological conditions and contributed to the launch of therapies like OPZELURA and povorcitinib [2][3] - His prior experience includes senior roles at Sun Pharma and Johnson & Johnson, where he contributed to the success of multiple high-impact therapies in dermatology and immunology [3] Strategic Vision - Dr. Patel emphasizes the importance of rigorous science and strong clinical evidence in advancing therapies for rare skin diseases, aligning with Palvella's mission-driven approach [4] - The QTORIN™ platform is seen as a pioneering solution with the potential to transform treatment paradigms for rare skin diseases by addressing their underlying pathobiology [4]

Financial Performance - Worldwide sales for Q1 2025 reached $219 billion, a 24% increase compared to Q1 2024, with operational sales growth of 42%[52] - Adjusted earnings for Q1 2025 were $67 billion, resulting in adjusted EPS of $277, a 22% increase[54] - The company is increasing its 2025 operational sales guidance midpoint by $07 billion to 38% due to the Intra-Cellular Therapies (ITCI) acquisition[72] Innovative Medicine - Innovative Medicine achieved 42% operational sales growth in Q1 2025, driven by key brands growing in double digits[15] - Oncology sales reached $5678 million, demonstrating strong growth[57] - TREMFYA showed superiority versus STELARA in endoscopic endpoints in Crohn's disease, with 34% of patients achieving deep remission at 1 year[42] MedTech - MedTech reported 41% operational sales growth in Q1 2025, with strong performance across Abiomed, Shockwave, Vision, and Wound Closure[17, 59] - Cardiovascular sales increased by 177% operationally[60] - Orthopaedics experienced a (31)% operational decrease, impacted by one-time events[62] Pipeline and Milestones - RYBREVANT plus LAZCLUZE demonstrated a significant overall survival benefit in first-line EGFR-mutated non-small cell lung cancer, with a projected median OS improvement of more than 1 year[38] - Icotrokinra showed potential in treating plaque psoriasis, with 46% of patients achieving completely clear skin (IGA 0) and 75% among adolescents[49] - The company anticipates several milestones in 2025, including potential approvals for nipocalimab in gMG, RYBREVANT Sub-Q in NSCLC, and TREMFYA Sub-Q in UC[75]